Table 1.
Associations of breast cancer risk with newly identified risk variants: Results from the Asia Breast Cancer Consortium
| SNP (Allelesa) | Frequencyb | Locus (Positionc) | Closest gene (Annotation) | Stage | Per-allele association | P for heterogeneityf | |
|---|---|---|---|---|---|---|---|
| OR (95% CI)d | Pe | ||||||
| rs4951011 (G/A) | 0.282 | 1q32.1 (202,032,954) | ZC3H11A (Intron 2) | Stage 1 | 1.09 (1.02–1.17) | 0.007 | |
| Stage 2 | 1.10 (1.02–1.18) | 0.011 | |||||
| Stage 3 | 1.08 (1.05–1.12) | 1.02 × 10−5 | |||||
| Combined | 1.09 (1.06–1.12) | 8.82 × 10−9 | 0.98 | ||||
| rs10474352 (C/T) | 0.482 | 5q14.3 (90,767,981) | ARRDC3 (Intergenic) | Stage 1 | 1.09 (1.03–1.17) | 0.006 | |
| Stage 2 | 1.12 (1.05–1.20) | 7.06 × 10−4 | |||||
| Stage 3 | 1.08 (1.04–1.12) | 1.92 × 10−5 | |||||
| Combined | 1.09 (1.06–1.12) | 1.67 × 10−9 | 0.50 | ||||
| rs2290203 (G/A) | 0.504 | 15q26.1 (89,313,071) | PRC1 (Intron 14) | Stage 1 | 1.08 (1.02–1.14) | 0.012 | |
| Stage 2 | 1.19 (1.10–1.30) | 4.97 × 10−5 | |||||
| Stage 3 | 1.06 (1.03–1.10) | 2.45 × 10−4 | |||||
| Combined | 1.08 (1.05–1.11) | 4.25 × 10−8 | 0.06 | ||||
Abbreviations: OR, odds ratio; CI, confidence interval.
a
Risk/reference allele; risk allele is shown in bold.
b
Risk allele frequency in controls from all three stages combined.
c
Chromosome position (bp) based on NCBI Human Genome Build 36.
d
Per-allele OR (95% CI) was adjusted for age and principal components in each study; summary OR (95% CI) was obtained using fixed-effect meta-analysis in each stage.
e
Derived from a weighted z-statistic–based meta-analysis.
f
P for heterogeneity across studies in all stages was calculated using Cochran’s Q test.